We help advanced imaging and frontier research equipment with strong technical
value and cost advantages enter U.S. research settings, combining expert collaboration
between the U.S. and China, joint research, publication support, and grant development
to build pathways from research collaboration toward clinical translation.
Centered on U.S. clinical data collaboration, real-world evidence, and data-driven
research support, we help relevant technologies, AI systems, medical devices,
and innovative programs explore more evidence-grounded pathways for research
validation, market entry, and commercialization. For opportunities that require a
better understanding of the U.S. clinical data environment, research feasibility,
and evidence-generation logic, .we can work with leading U.S. clinical data platform
partners and resources to support more practical pathway design and coordinated
execution.
If cross-border collaboration in healthcare is reduced to simply “selling a product into another country,”
the complexity of the work is immediately underestimated. What determines whether cooperation actually
happens is usually not the product alone, but whether the product, technology, or opportunity can find …
Many Chinese advanced equipment teams looking at the U.S. market fall into the same assumption: if the technology is leading, the cost structure is better, and the product is new enough, then the next
step should be direct clinical commercialization. It sounds intuitive, but in the U.S. healthcare system…
“We have resources.” That is probably one of the most common statements in cross-border collaboration.
The problem is that in healthcare, many real opportunities are not made successful by “having resources”
alone. The hardest part is rarely meeting a person, reaching an institution, or arranging a meeting. The …
Many platform companies face the same problem: as the business expands, outsiders begin to feel that the
number of directions is increasing while the logic behind them is becoming less clear. One day the company
is doing medical consumables, then research equipment, then AI systems, rapid testing products, health…
Conversations about health AI over the past few years have often centered on a familiar question: Is the
model smart enough, is the algorithm advanced enough, and is the accuracy high enough? Today, that
conversation is shifting. What increasingly determines whether a health AI product can earn long-term…
Many healthcare technologies historically approached the U.S. market through a familiar sequence:
regulatory approval, channel access, customer development, and sales. Once market clearance was secured
and a distributor or customer entry point was identified, the market could supposedly open over time. That …